Literature DB >> 16860338

Effect of comorbid tics on a clinically meaningful response to 8-week open-label trial of fluoxetine in obsessive compulsive disorder.

David S Husted1, Nathan A Shapira, Tanya K Murphy, Giselle D Mann, Herbert E Ward, Wayne K Goodman.   

Abstract

Currently, there are limited published data evaluating the effects of tics on serotonin reuptake inhibitor (SRI) monotherapy responses in treating obsessive-compulsive disorder (OCD). One retrospective case-controlled analysis of OCD patients treated with SRI monotherapy showed lesser improvement in OCD symptoms in patients with tics than those without. However, more recently there were preliminary reports of OCD subjects treated with SRI monotherapy which did not demonstrate poorer response in subjects with tics or Tourette's Syndrome (TS). The specific aim of this study was to investigate whether the presence of comorbid chronic tics affected "clinically meaningful improvement" [McDougle, C.J., Goodman, W.K., Leckman, J.F., Barr, L.C., Heninger, G.R., Price, L.H., 1993. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder. Journal of Clinical Psychopharmacology 13, 354-358] of OCD in an 8-week open-label trial of fluoxetine monotherapy. Seventy-four adult subjects (13 patients with comorbid chronic tics and 61 patients without tics) with a primary DSM-IV OCD diagnosis were treated with up to 40mg fluoxetine for 8 weeks and had at least one post-baseline evaluation. The results indicate that there was a significant response by time in both fluoxetine-with-tic subjects and fluoxetine-without-tic subjects. Additionally, there were 3 (23.0%) OCD subjects with tics who had clinically meaningful improvement versus 16 (26.2%) OCD subjects without tics that demonstrated similar levels of improvement. These findings indicate that OCD patients with or without chronic tic disorders did not have a differential response to an 8-week open-label trial of fluoxetine. Limitations include the relatively low number of tic subjects and the open-label nature of the study. Additional data are needed on how comorbid tics may affect SRI treatment response in OCD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16860338     DOI: 10.1016/j.jpsychires.2006.05.007

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  6 in total

1.  Presentation of psoriatic arthritis in the literature: a twenty-year bibliometric evaluation.

Authors:  Ahmad-Reza Jamshidi; Farhad Gharibdoost; Abdolhadi Nadji; Mohammadali Nikou; Gholamreza Habibi; Amirhossein Mardani; Marjan Ghaemi
Journal:  Rheumatol Int       Date:  2012-03-27       Impact factor: 2.631

2.  Pediatric obsessive-compulsive disorder with tic symptoms: clinical presentation and treatment outcome.

Authors:  Davíð R M A Højgaard; Gudmundur Skarphedinsson; Judith Becker Nissen; Katja A Hybel; Tord Ivarsson; Per Hove Thomsen
Journal:  Eur Child Adolesc Psychiatry       Date:  2016-12-28       Impact factor: 4.785

3.  Tics Moderate Sertraline, but Not Cognitive-Behavior Therapy Response in Pediatric Obsessive-Compulsive Disorder Patients Who Do Not Respond to Cognitive-Behavior Therapy.

Authors:  Gudmundur Skarphedinsson; Scott Compton; Per Hove Thomsen; Bernhard Weidle; Kitty Dahl; Judith Becker Nissen; Nor Christian Torp; Katja Hybel; Karin Holmgren Melin; Robert Valderhaug; Tore Wentzel-Larsen; Tord Ivarsson
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-06       Impact factor: 2.576

Review 4.  Psychopharmacotherapy of Obsessive-Compulsive Symptoms within the Framework of Tourette Syndrome.

Authors:  Aribert Rothenberger; Veit Roessner
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

5.  A population-based family clustering study of tic-related obsessive-compulsive disorder.

Authors:  Gustaf Brander; Ralf Kuja-Halkola; Mina A Rosenqvist; Christian Rück; Eva Serlachius; Lorena Fernández de la Cruz; Paul Lichtenstein; James J Crowley; Henrik Larsson; David Mataix-Cols
Journal:  Mol Psychiatry       Date:  2019-10-15       Impact factor: 15.992

6.  Lung adenocarcinoma-related target gene prediction and drug repositioning.

Authors:  Rui Xuan Huang; Damrongrat Siriwanna; William C Cho; Tsz Kin Wan; Yan Rong Du; Adam N Bennett; Qian Echo He; Jun Dong Liu; Xiao Tai Huang; Kei Hang Katie Chan
Journal:  Front Pharmacol       Date:  2022-08-23       Impact factor: 5.988

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.